GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (FRA:TCE2) » Definitions » Research & Development

Celldex Therapeutics (FRA:TCE2) Research & Development : €134.68 Mil (TTM As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Celldex Therapeutics's Research & Development for the three months ended in Sep. 2024 was €40.78 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was €134.68 Mil.

Celldex Therapeutics Research & Development Historical Data

The historical data trend for Celldex Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Research & Development Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.41 34.96 47.18 77.65 108.22

Celldex Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.36 27.90 29.13 36.87 40.78

Celldex Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €134.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics  (FRA:TCE2) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Celldex Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (FRA:TCE2) » Definitions » Research & Development
Comparable Companies
ARVN FTRE XNCR TARS NAMS MNKD IRON HRMY SYRE VRDN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CLDX:USA TCE2:Germany
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Website
https://www.celldex.com
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics Headlines

No Headlines